Frank Bedu-Addo,Greg Conn,Siva K. Gandhapudi,Martin Ward,Jerold Woodward
申请号:
US16532728
公开号:
US20190358319A1
申请日:
2019.08.06
申请国别(地区):
US
年份:
2019
代理人:
摘要:
The invention covers the use of certain classes of lipids including cationic lipids in ex-vivo dendritic cell therapies. The cationic lipids enhance antigen uptake, processing and presentation of the processed antigens by dendritic cells to CD8+and CD4+T-cells via the MHC classes I and II presentation pathways respectively. Antigen uptake via cationic lipid by dendritic cells result in significant lowering of the population of the immune suppressive regulatory T cells in the tumors and a significant increase of the tumor targeting cytotoxic T-cells. Loss of regulatory T cells and increase of tumor specific cytotoxic cells are conducive to effective elimination of the tumors.